Orthofix Up +3.9% in 2Q19 on Biologics Outperformance


Orthofix grew in the low single digits in 2Q19 as abnormally high price pressure on spinal hardware was offset by increased Trinity allograft volume.

Company reiterated previous 2019 revenue guidance
Jon Serbousek will succeed Bradley Mason as President and CEO on November 1, and will take the role of President of Global...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us